Hesperidin (SHINJIMUN) blood perfusion trial

JRCT ID: jRCTs071200042

Registered date:13/10/2020

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: N/A
• Date of first enrollment: 13/10/2020
• Target sample size: 14
• Study type: Interventional

Intervention(s)

Arm A:Fermented Shekwasa (SHINJIMUN) 4 tabs/day given on day 1 to 7 and then Placebo 4 tab/day given on day 8 to 14.
Arm B:Placebo 4 tabs/day given on day 1 to 8 then ermented Shekwasa (SHINJIMUN) 4 tab/day given on day 8 to 14

Outcome(s)

• Primary Outcome: Amount of Peripheral blood perfusion (ml/min)

Secondary Outcome

1. Serum Hesperetin concentration
2. Intracranial SpO2 (%)
3. Serum Hexanoyl Lysine concentration
4. Stool
5. Serum Triglyceride level

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: < 70age old
• Gender: Both

Include criteria

1. Male and female patients, 20-70 years old
2. Written informed consent
3. For participants taking medications (including supplements and dietary supplements), those who have not changed their dosage and administration during the study period

Exclude criteria

1. Renal dysfunction (eGFR<30ml/min/1.73m2)
2. Liver cirrhosis
3. Clinical evidence of cholestasis
4. Active cancer
5. Pregnant or lactating female
6. Participant deemed inadequate to this study

Related Information

• Primary Sponsor: Inafuku Hitoshi
• Source(s) of Monetary Support: CATARIST RYUKYU